Source: Eur Respir J, 58 (6) 2101313; 10.1183/13993003.01313-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Lynn Elsey, Thomas Pantin, Leanne-Jo Holmes, Gael Tavernier, Stephen J. Fowler. Outcomes over the first two years of treatment with mepolizumab in severe asthma. Eur Respir J, 58 (6) 2101313; 10.1183/13993003.01313-2021

Member's Comments

No comment yet.

Related content which might interest you: Severe asthma outcomes over two years of therapy with mepolizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Severe asthma outcomes over 18-months treatment with mepolizumab, and comorbidities in non-responders. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Exacerbations of severe asthma in patients treated with mepolizumab Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018 Year: 2018 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 A longitudinal follow-up of severe asthma patients receiving reslizumab Source: International Congress 2017 – Asthma management Year: 2017 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Safety of tiotropium in pre-school children with symptomatic persistent asthma Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies Year: 2016